Telix Pharmaceuticals Limited (NASDAQ:TLX) Short Interest Update

Telix Pharmaceuticals Limited (NASDAQ:TLX) was the target of a significant increase in short interest in the month of July. As of July 15th, there was short interest totaling 297,140 shares, an increase of 82.7% from the June 30th total of 162,625 shares. Based on an average daily trading volume, of 165,030 shares, the short-interest ratio is currently 1.8 days. Approximately 0.1% of the company’s shares are short sold.

Telix Pharmaceuticals Stock Performance

Shares of NASDAQ:TLX opened at $10.06 on Friday. Telix Pharmaceuticals has a 12-month low of $6.28 and a 12-month high of $14.27. The stock has a fifty day simple moving average of $10.33 and a two-hundred day simple moving average of $9.24. The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.08.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Hennion & Walsh Asset Management Inc. bought a new stake in Telix Pharmaceuticals in the second quarter worth $1,731,000. Bank of America Corp DE raised its position in Telix Pharmaceuticals by 523.8% during the 1st quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock valued at $96,000 after purchasing an additional 8,423 shares in the last quarter. Lazard Asset Management LLC grew its holdings in Telix Pharmaceuticals by 15.7% during the 1st quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock worth $2,775,000 after acquiring an additional 39,400 shares in the last quarter. XY Capital Ltd purchased a new stake in Telix Pharmaceuticals during the first quarter worth $120,000. Finally, Private Advisor Group LLC boosted its position in Telix Pharmaceuticals by 276.3% during the first quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock valued at $1,669,000 after purchasing an additional 128,070 shares in the last quarter.

Wall Street Analyst Weigh In

Several research analysts have recently commented on TLX shares. Wall Street Zen upgraded Telix Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, April 11th. Wedbush restated an “outperform” rating and set a $22.00 target price on shares of Telix Pharmaceuticals in a report on Monday, July 6th. Weiss Ratings restated a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Friday, July 17th. HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Telix Pharmaceuticals in a research report on Tuesday, July 7th. Finally, Citigroup decreased their price target on Telix Pharmaceuticals from $22.50 to $22.00 and set a “buy” rating on the stock in a research note on Tuesday, July 7th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $20.40.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.